| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EEF1a2 |
| Uniprot No | Q05639 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-463aa |
| 氨基酸序列 | MGKEKTHINIVVIGHVDSGKSTTTGHLIYKCGGIDKRTIEKFEKEAAEMGKGSFKYAWVLDKLKAERERGITIDISLWKFETTKYYITIIDAPGHRDFIKNMITGTSQADCAVLIVAAGVGEFEAGISKNGQTREHALLAYTLGVKQLIVGVNKMDSTEPAYSEKRYDEIVKEVSAYIKKIGYNPATVPFVPISGWHGDNMLEPSPNMPWFKGWKVERKEGNASGVSLLEALDTILPPTRPTDKPLRLPLQDVYKIGGIGTVPVGRVETGILRPGMVVTFAPVNITTEVKSVEMHHEALSEALPGDNVGFNVKNVSVKDIRRGNVCGDSKSDPPQEAAQFTSQVIILNHPGQISAGYSPVIDCHTAHIACKFAELKEKIDRRSGKKLEDNPKSLKSGDAAIVEMVPGKPMCVESFSQYPPLGRFAVRDMRQTVAVGVIKNVEKKSGGAGKVTKSAQKAQKAGK |
| 预测分子量 | 50,4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为示例性质的参考文献(具体文献请通过学术数据库查询)：
---
1. **文献名称**：*"Recombinant EEF1A2 Protein Expression and Purification for Structural Studies"*
**作者**：Johnson, M. et al.
**摘要**：研究报道了在大肠杆菌中高效表达重组人EEF1A2蛋白的优化方法，通过亲和层析纯化获得高纯度蛋白，并利用X射线晶体学解析其三维结构，揭示了与GTP结合的关键结构域。
---
2. **文献名称**：*"EEF1A2 Overexpression in Breast Cancer: Role of Recombinant Protein in Cell Proliferation"*
**作者**：Smith, R. & Lee, K.
**摘要**：通过体外重组EEF1A2蛋白处理乳腺癌细胞，发现其显著促进细胞增殖和迁移，并激活mTOR信号通路，提示其作为癌症治疗潜在靶点的可能性。
---
3. **文献名称**：*"Functional Characterization of EEF1A2 Mutants in Neurological Disorders Using Recombinant Protein Assays"*
**作者**：Chen, Y. et al.
**摘要**：构建了与神经发育疾病相关的EEF1A2突变体重组蛋白，通过体外翻译系统证明特定突变导致蛋白功能缺陷，为致病机制提供了分子证据。
---
4. **文献名称**：*"Development of a Recombinant EEF1A2-Specific Monoclonal Antibody for Diagnostic Applications"*
**作者**：Wang, H. et al.
**摘要**：利用重组EEF1A2蛋白作为抗原，成功制备高特异性单克隆抗体，验证其在肺癌组织样本中的免疫组化检测效能，显示其在临床诊断中的潜在价值。
---
建议通过 **PubMed** 或 **Google Scholar** 以关键词“EEF1A2 recombinant protein”检索最新文献，获取更权威信息。
**Background of EEF1A2 Recombinant Protein**
The **Eukaryotic Translation Elongation Factor 1 Alpha 2 (EEF1A2)** is a member of the elongation factor family critical for protein synthesis. It facilitates the GTP-dependent binding of aminoacyl-tRNA to the ribosome during the elongation phase of translation. While its paralog, EEF1A1. is ubiquitously expressed, EEF1A2 exhibits tissue-specific expression, predominantly in neurons, muscle, and certain cancers. This restricted expression pattern suggests specialized roles in development and cellular homeostasis.
EEF1A2 gained attention due to its association with human diseases. Mutations in *EEF1A2* are linked to severe neurodevelopmental disorders, including epilepsy and intellectual disability. Additionally, its dysregulation is observed in cancers (e.g., breast, ovarian, and lung), where it acts as an oncoprotein by promoting cell proliferation, survival, and metastasis. These findings highlight its dual role as both a developmental regulator and a potential therapeutic target.
Recombinant EEF1A2 protein is engineered for functional studies and therapeutic exploration. Produced via heterologous expression systems (e.g., *E. coli* or mammalian cells), the recombinant protein retains structural and functional integrity, including GTPase activity and tRNA-binding capacity. It is utilized to investigate molecular mechanisms of disease-associated mutations, screen for inhibitors in cancer research, and develop diagnostic tools.
Moreover, recombinant EEF1A2 serves as an antigen for antibody generation, aiding in biomarker detection in clinical samples. Its study bridges gaps in understanding translational regulation in specialized tissues and offers avenues for targeted therapies in neurology and oncology.
×
